GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's ...

GSK是一家覆盖抗感染、中枢神经系统、呼吸科、肠胃／代谢 ... 她拥有印度马德拉斯大学维洛尔理工学院（Vellore Institute of Technology）电子工程学士学位。 从硅谷到制药：理念与现实的碰撞 拉玛克里希南的一句名言，“我们不是为了技术而技术”，道出了她 ...

Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio. The purchase ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Hanon meanwhile is joined at Vicebio by two other ex-GSK staffers – Dr Giovanni Della Cioppa and Dr Jean Smal – who will serve as chief medical officer and chief technology officer ...

Dec 20 (Reuters) - GSK (GSK.L), opens new tab said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance therapy improved survival in ...

Under terms of the deal, GSK will also acquire IDRX-42, a tyrosine kinase inhibitor designed to treat both primary and secondary KIT mutations in patients with gastrointestinal stromal tumors. GSK ...

The acquisition of IDRx will help GSK target a ‘major gap in the current standard of care’ related to gastrointestinal cancers.